Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 16;12(7):250697.
doi: 10.1098/rsos.250697. eCollection 2025 Jul.

Enzyme inhibitory activity of marine alkaloid aaptamines for neurodegenerative diseases: an in silico study

Affiliations

Enzyme inhibitory activity of marine alkaloid aaptamines for neurodegenerative diseases: an in silico study

Thi Le Anh Nguyen et al. R Soc Open Sci. .

Abstract

The enzyme inhibitory activities of a dataset of 28 aaptamines are performed to identify potential multifunctional drugs for neurodegenerative diseases (NDs). First, the drug-like properties and pharmacokinetic (ADMET) study excluded seven molecules, mostly for the non-permeability of the blood-brain barrier. The binding activities of the remaining 21 candidates towards acetylcholinesterase (AChE), monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) enzymes are initially screened by molecular docking. The top binding complexes (A12@MAOB, A24@COMT and A27@AChE) are simultaneously studied by molecular dynamics in water for 500 ns time-scale and compared with the references such as safinamide (SAG), tolcapone (TOL) or donepezil (DON). The results show that two aaptamines A12 and A27 are well-positioned within the active pocket of the enzymes, exhibiting structural stability, with a root mean square deviation of about 0.15-0.2 nm. MM-PBSA calculation indicates that the binding energy of the ligands to the corresponding targets is equal to (A12 versus SAG) or much lower than the references (A24 versus TOL and A27 versus DON). The van der Waals interactions contribute more strongly to enzyme binding than the electrostatic energy. The study results suggest that A27 (lowest binding energy, -170.42 ± 14.24 kJ mol-1) is the most prominent aaptamine candidate for the treatment of NDs.

Keywords: ADMET; aaptamines; docking; enzyme inhibition; molecular dynamics; neurodegenerative diseases.

PubMed Disclaimer

Conflict of interest statement

We declare we have no competing interests.

Figures

Structures of aaptamine A1–A28 used in this work.
Figure 1.
Structures of aaptamines A1A28 used in this work. Aaptamine A1 is presented with position numbering.
BOILED-Egg prediction of set B (A1–A27).
Figure 2.
BOILED-Egg prediction of set B (A1A27).
Time-dependent RMSD (nm) of the complexes in the time range 500 ns.
Figure 3.
Time-dependent RMSD (nm) of the complexes in the time range 500 ns. Each complex is presented with three independent trajectories.
Number of H-bonds for selected trajectories of the complexes.
Figure 4.
Number of H-bonds for selected trajectories of the complexes A12@MAOB, A24@COMT and A27@AChE (top) and their corresponding references (bottom) along the time scale of 500 ns
Total energy of A27@AChE and DON@AChE in relationship with the number of H-bonds of the complexes.
Figure 5.
Total energy of A27@AChE and DON@AChE in relationship with the number of H-bonds of the complexes.
2D and 3D illustrative images of the binding pose of A27 in AChE.
Figure 6.
2D and 3D illustrative images of the binding pose of A27 in AChE. The results are obtained by clustering the Cα and heavy atoms of ligand with a cut-off 0.25 nm using MD snapshots.
The occupied cavities of A27 (magenta) and DON (gold) in the catalytic active sites of AChE after alignment.
Figure 7.
The occupied cavities of A27 (magenta) and DON (gold) in the catalytic active sites of AChE after alignment.

Similar articles

References

    1. Erkkinen MG, Kim MO, Geschwind MD. 2018. Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb. Perspect. Biol. 10, a033118. ( 10.1101/cshperspect.a033118) - DOI - PMC - PubMed
    1. Kovacs GG. 2018. Concepts and classification of neurodegenerative diseases. Handb. Clin. Neurol. 145, 301–307. ( 10.1016/B978-0-12-802395-2.00021-3) - DOI - PubMed
    1. Hansson O. 2021. Biomarkers for neurodegenerative diseases. Nat. Med. 27, 954–963. ( 10.1038/s41591-021-01382-x) - DOI - PubMed
    1. Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M. 2015. The global impact of dementia: an analysis of prevalence, incident, cost and trends. London, UK: Alzheimer’s Disease International (ADI).
    1. Uddin MS, Mamun AA, Kabir MT, Ashraf GM, Bin-Jumah MN, Abdel-Daim MM. 2021. Multi-target drug candidates for multifactorial Alzheimer’s disease: AChE and NMDAR as molecular targets. Mol. Neurobiol. 58, 281–303. ( 10.1007/s12035-020-02116-9) - DOI - PubMed

LinkOut - more resources